Show Navigation

Image 1 of 1

ALZHEIMER BLOOD 09.jpg

ST. LOUIS - Sept. 9, 2022: Scott Harpstrite, laboratory manager at C2N Diagnostics, displays frozen blood samples awaiting processing at the company’s laboratory in St. Louis Friday, Sept. 9, 2022. The firm’s blood test uses an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)
Copyright
© Sid Hastings
Image Size
6000x3792 / 10.6MB
https://www.sidhastings.com/p/image-license-or-pur
https://www.sidhastings.com/contact
Contained in galleries
ST. LOUIS - Sept. 9, 2022: Scott Harpstrite, laboratory manager at C2N Diagnostics, displays frozen blood samples awaiting processing at the company’s laboratory in St. Louis Friday, Sept. 9, 2022. The firm’s blood test uses an in vitro diagnostic laboratory-developed test for brain amyloid detection, a pathologic hallmark of Alzheimer’s disease. (Photo by Sid Hastings/For The Washington Post)